CAS 1815580-06-3

HDAC6-IN-1

Description:

HDAC6-IN-1, identified by its CAS number 1815580-06-3, is a small molecule inhibitor specifically targeting histone deacetylase 6 (HDAC6). This enzyme plays a crucial role in the regulation of various cellular processes, including gene expression, protein degradation, and cell signaling. HDAC6 is particularly involved in the deacetylation of non-histone proteins, influencing cellular stress responses and the immune system. The inhibition of HDAC6 has garnered interest in therapeutic applications, particularly in cancer treatment and neurodegenerative diseases, as it can lead to the accumulation of acetylated proteins, promoting apoptosis in cancer cells and enhancing neuroprotective mechanisms. HDAC6-IN-1 is characterized by its selective inhibition profile, which minimizes off-target effects associated with broader HDAC inhibitors. Its chemical structure typically includes functional groups that facilitate binding to the active site of HDAC6, enhancing its potency and efficacy. Ongoing research continues to explore its pharmacological properties, potential side effects, and therapeutic applications in various disease models.

Formula: C₂₁H₂₄N₄O₄

Synonyms:

• Butanamide, N-hydroxy-4-[2-methoxy-5-[methyl(2-methyl-4-quinazolinyl)amino]phenoxy]-
• HDAC6-IN-1
• SKLB-23bb

SKLB-23bb

CAS: 1815580-06-3

SKLB-23bb

Purity: ≥95%

Molecular weight: 396.44g/mol

Ref: 54-BUP08760

SKLB-23bb

CAS: 1815580-06-3

SKLB-23bb is an orally bioavailable HDAC6-selective inhibitor and also has microtubule-disrupting ability.

Formula: C₂₁H₂₄N₄O₄

Purity: 97.58%

Color and Shape: Solid

Molecular weight: 396.44

Ref: TM-T5830

SKLB-23bb

CAS: 1815580-06-3

SKLB-23bb is a small molecule that inhibits the polymerization of microtubules. It inhibits the assembly and stability of microtubules by binding to tubulin, preventing the formation of stable polymers. SKLB-23bb has been shown to be effective in inhibiting tumor growth in xenografts in mice. It also inhibits the proliferation of cancer cells, but not normal cells, which may be due to its ability to inhibit gene transcription. This drug also has a number of modifications, such as a hydroxy group, that allow it to be orally administered and modified with colchicine. These modifications make SKLB-23bb an attractive candidate for cancer therapy.

Formula: C₂₁H₂₄N₄O₄

Purity: Min. 95%

Molecular weight: 396.44 g/mol

Ref: 3D-QXC58006